Upadacitinib (Rinvoq)
Drug timelines are a Plus or Pro feature.
6 regulatory and trial events tracked for Upadacitinib (Rinvoq), covering 2024-11-18 to 2026-03-04. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy [Phase 3]